Literature DB >> 23233540

Lipoprotein remodeling generates lipid-poor apolipoprotein A-I particles in human interstitial fluid.

Norman E Miller1, Waldemar L Olszewski, Hiroaki Hattori, Irina P Miller, Takeshi Kujiraoka, Tomoichiro Oka, Tadao Iwasaki, M Nazeem Nanjee.   

Abstract

Although much is known about the remodeling of high density lipoproteins (HDLs) in blood, there is no information on that in interstitial fluid, where it might have a major impact on the transport of cholesterol from cells. We incubated plasma and afferent (prenodal) peripheral lymph from 10 healthy men at 37°C in vitro and followed the changes in HDL subclasses by nondenaturing two-dimensional crossed immunoelectrophoresis and size-exclusion chromatography. In plasma, there was always initially a net conversion of small pre-β-HDLs to cholesteryl ester (CE)-rich α-HDLs. By contrast, in lymph, there was only net production of pre-β-HDLs from α-HDLs. Endogenous cholesterol esterification rate, cholesteryl ester transfer protein (CETP) concentration, CE transfer activity, phospholipid transfer protein (PLTP) concentration, and phospholipid transfer activity in lymph averaged 5.0, 10.4, 8.2, 25.0, and 82.0% of those in plasma, respectively (all P < 0.02). Lymph PLTP concentration, but not phospholipid transfer activity, was positively correlated with that in plasma (r = +0.63, P = 0.05). Mean PLTP-specific activity was 3.5-fold greater in lymph, reflecting a greater proportion of the high-activity form of PLTP. These findings suggest that cholesterol esterification rate and PLTP specific activity are differentially regulated in the two matrices in accordance with the requirements of reverse cholesterol transport, generating lipid-poor pre-β-HDLs in the extracellular matrix for cholesterol uptake from neighboring cells and converting pre-β-HDLs to α-HDLs in plasma for the delivery of cell-derived CEs to the liver.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23233540      PMCID: PMC3566430          DOI: 10.1152/ajpendo.00324.2012

Source DB:  PubMed          Journal:  Am J Physiol Endocrinol Metab        ISSN: 0193-1849            Impact factor:   4.310


  56 in total

1.  Very small apolipoprotein A-I-containing particles from human plasma: isolation and quantification by high-performance size-exclusion chromatography.

Authors:  M N Nanjee; E A Brinton
Journal:  Clin Chem       Date:  2000-02       Impact factor: 8.327

2.  Distribution of phospholipid transfer protein in human plasma: presence of two forms of phospholipid transfer protein, one catalytically active and the other inactive.

Authors:  T Oka; T Kujiraoka; M Ito; T Egashira; S Takahashi; M N Nanjee; N E Miller; J Metso; V M Olkkonen; C Ehnholm; M Jauhiainen; H Hattori
Journal:  J Lipid Res       Date:  2000-10       Impact factor: 5.922

Review 3.  Microvascular fluid exchange and the revised Starling principle.

Authors:  J Rodney Levick; C Charles Michel
Journal:  Cardiovasc Res       Date:  2010-03-03       Impact factor: 10.787

4.  Evaluation of phospholipid transfer protein and cholesteryl ester transfer protein as contributors to the generation of pre beta-high-density lipoproteins.

Authors:  J Lie; R de Crom; M Jauhiainen; T van Gent; R van Haperen; L Scheek; H Jansen; C Ehnholm; A van Tol
Journal:  Biochem J       Date:  2001-12-01       Impact factor: 3.857

5.  Composition and ultrastructure of size subclasses of normal human peripheral lymph lipoproteins: quantification of cholesterol uptake by HDL in tissue fluids.

Authors:  M N Nanjee; C J Cooke; J S Wong; R L Hamilton; W L Olszewski; N E Miller
Journal:  J Lipid Res       Date:  2001-04       Impact factor: 5.922

Review 6.  The impact of phospholipid transfer protein (PLTP) on HDL metabolism.

Authors:  J Huuskonen; V M Olkkonen; M Jauhiainen; C Ehnholm
Journal:  Atherosclerosis       Date:  2001-04       Impact factor: 5.162

7.  Concentrations of electrophoretic and size subclasses of apolipoprotein A-I-containing particles in human peripheral lymph.

Authors:  M N Nanjee; C J Cooke; W L Olszewski; N E Miller
Journal:  Arterioscler Thromb Vasc Biol       Date:  2000-09       Impact factor: 8.311

8.  Lipid and apolipoprotein concentrations in prenodal leg lymph of fasted humans. Associations with plasma concentrations in normal subjects, lipoprotein lipase deficiency, and LCAT deficiency.

Authors:  M N Nanjee; C J Cooke; W L Olszewski; N E Miller
Journal:  J Lipid Res       Date:  2000-08       Impact factor: 5.922

9.  Human apoA-I increases macrophage foam cell derived PLTP activity without affecting the PLTP mass.

Authors:  Marius R Robciuc; Jari Metso; Anca Sima; Christian Ehnholm; Matti Jauhiainen
Journal:  Lipids Health Dis       Date:  2010-06-09       Impact factor: 3.876

10.  Two novel missense mutations in the CETP gene in Japanese hyperalphalipoproteinemic subjects: high-throughput assay by Invader assay.

Authors:  Makoto Nagano; Shizuya Yamashita; Ken-ichi Hirano; Mayumi Ito; Takao Maruyama; Mitsuaki Ishihara; Yukiko Sagehashi; Tomoichiro Oka; Takeshi Kujiraoka; Hiroaki Hattori; Norimichi Nakajima; Tohru Egashira; Masatoshi Kondo; Naohiko Sakai; Yuji Matsuzawa
Journal:  J Lipid Res       Date:  2002-07       Impact factor: 5.922

View more
  17 in total

1.  LDL and HDL transfer rates across peripheral microvascular endothelium agree with those predicted for passive ultrafiltration in humans.

Authors:  C Charles Michel; M Nazeem Nanjee; Waldemar L Olszewski; Norman E Miller
Journal:  J Lipid Res       Date:  2014-11-14       Impact factor: 5.922

2.  Enhanced vascular permeability facilitates entry of plasma HDL and promotes macrophage-reverse cholesterol transport from skin in mice.

Authors:  Ilona Kareinen; Lídia Cedó; Reija Silvennoinen; Pirkka-Pekka Laurila; Matti Jauhiainen; Josep Julve; Francisco Blanco-Vaca; Joan Carles Escola-Gil; Petri T Kovanen; Miriam Lee-Rueckert
Journal:  J Lipid Res       Date:  2014-12-03       Impact factor: 5.922

Review 3.  Lymphatic transport of high-density lipoproteins and chylomicrons.

Authors:  Gwendalyn J Randolph; Norman E Miller
Journal:  J Clin Invest       Date:  2014-03-03       Impact factor: 14.808

Review 4.  HDL-targeted therapies: progress, failures and future.

Authors:  Bronwyn A Kingwell; M John Chapman; Anatol Kontush; Norman E Miller
Journal:  Nat Rev Drug Discov       Date:  2014-05-23       Impact factor: 84.694

5.  Interleukin-17 Drives Interstitial Entrapment of Tissue Lipoproteins in Experimental Psoriasis.

Authors:  Li-Hao Huang; Bernd H Zinselmeyer; Chih-Hao Chang; Brian T Saunders; Andrew Elvington; Osamu Baba; Thomas J Broekelmann; Lina Qi; Joseph S Rueve; Melody A Swartz; Brian S Kim; Robert P Mecham; Helge Wiig; Michael J Thomas; Mary G Sorci-Thomas; Gwendalyn J Randolph
Journal:  Cell Metab       Date:  2018-11-08       Impact factor: 27.287

Review 6.  HDL and Reverse Cholesterol Transport.

Authors:  Mireille Ouimet; Tessa J Barrett; Edward A Fisher
Journal:  Circ Res       Date:  2019-05-10       Impact factor: 17.367

7.  HDL and Lipid Metabolism.

Authors:  Qi Zhang; Yilang Ke; Huashan Hong
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 2.622

8.  Chymase released from hypoxia-activated cardiac mast cells cleaves human apoA-I at Tyr192 and compromises its cardioprotective activity.

Authors:  Ilona Kareinen; Marc Baumann; Su Duy Nguyen; Katariina Maaninka; Andrey Anisimov; Minoru Tozuka; Matti Jauhiainen; Miriam Lee-Rueckert; Petri T Kovanen
Journal:  J Lipid Res       Date:  2018-03-26       Impact factor: 5.922

9.  HDL particle size is increased and HDL-cholesterol efflux is enhanced in type 1 diabetes: a cross-sectional study.

Authors:  Mohamad O Ahmed; Rachel E Byrne; Agnieszka Pazderska; Ricardo Segurado; Weili Guo; Anjuli Gunness; Isolda Frizelle; Mark Sherlock; Khalid S Ahmed; Anne McGowan; Kevin Moore; Gerard Boran; Fiona C McGillicuddy; James Gibney
Journal:  Diabetologia       Date:  2020-11-09       Impact factor: 10.122

Review 10.  The role of the lymphatic system in cholesterol transport.

Authors:  Li-Hao Huang; Andrew Elvington; Gwendalyn J Randolph
Journal:  Front Pharmacol       Date:  2015-09-02       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.